The objective of this meta-analysis of randomized trials was to evaluate if the administration of furosemide with matched hydration using the RenalGuard System reduces contrast-induced acute kidney injury (CI-AKI) in patients undergoing interventional procedures.
. The incidence of CI-AKI is estimated to be 1% to 2% (5, 6) , but it may be significantly higher in patients with diabetes mellitus and pre-existing renal impairment (6) or in case of intra-arterial contrast administration (7); moreover, in patients with pre-existing renal impairment, the risk for CI-AKI can be as high as 50%. It is also procedure dependent, with 14.5% overall in patients undergoing percutaneous coronary interventions (8) compared with 1.6% to 2.3% for diagnostic intervention (9) . In patients undergoing percutaneous coronary intervention, each 100 ml of contrast was associated with a 12% increased risk for CI-AKI (10).
The optimal treatment for preventing CI-AKI has not yet been defined (2) : trials of N-acetylcysteine, diuretic agents, dopamine, calcium-channel blockers, atrial natriuretic peptides, aminophylline, statins, and endothelin antagonists have yielded contrasting results (2) . Only periprocedural hydration is widely accepted to prevent contrast nephropathy (2, 3, 11) .
Multiple kidney-protective strategies have been studied, but few have shown benefit in prospective randomized studies (12) . Recently, a novel system aimed at reducing CI-AKI was introduced in the market. The RenalGuard System (PLC Medical Systems, Milford, Massachusetts) delivers intravenous fluids matched to urine output with a combination of hydration with normal saline at an initial dose bolus plus a low dose of furosemide and continuous monitoring for a urine output flow of >300 ml/h sustained for 6 h (12).
The aim of our systematic review and metaanalysis was to evaluate if furosemide with matched hydration using the RenalGuard System effectively decreases the incidence of CI-AKI in patients undergoing interventional procedures.
METHODS
The present study was conducted in keeping with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (13); a complete checklist is provided in Online Table 1 . We registered the study protocol on the PROSPERO database of systematic reviews (CRD42016036208). The primary outcome of the present review was the incidence of CI-AKI. The secondary outcomes were need for RRT, mortality at longest follow-up available, acute coronary syndromes, stroke or transient ischemic attack, and adverse events. The outcomes were reported as per-study definition.
We rated the overall quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (14) . Putzu et al.
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FIGURE 1 Study Flow Diagram
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Putzu et al. Table 2 ). The trials were published between 2011 and 2016. All trials but 1 (29) had a single-center design. All trials were performed in Italy.
All trials used the RenalGuard System for the prevention of CI-AKI in patients undergoing coronary artery procedures (27) (28) (29) or transcatheter aortic valve replacement (26) . All trials administered specific treatments as control: isotonic saline (26, 28) , intravenous sodium bicarbonate plus Nacetylcysteine (29), or sodium bicarbonate plus isotonic saline plus N-acetylcysteine plus vitamin C (27) . Interventions' regimens are reported in detail in Online Table 3 .
Trials performed in the setting of coronary procedures enrolled patients with pre-operative kidney impairment, whereas transcatheter aortic valve replacement trials enrolled all patients regardless of their kidney function ( (27) . Different CI-AKI definitions were used ( Table 1) .
All trials scored 4 of 6 points in the modified Jadad/ Oxford quality scale and were judged to be at high risk of bias according to Cochrane methodology (Online Table 4 ). None of the trials was blinded, although the difficulty of blinding patients and personnel should be acknowledged given the nature of the intervention. Table 5 ).
Meta-regression failed to find any significant correlation with age and GFR at randomization (Online Appendix). The sensitivity analyses of the primary outcome confirmed the results (Online Table 6 RenalGuard therapy was found to significantly decrease both contrast-induced acute kidney injury (CI-AKI) and renal replacement therapy. CI ¼ confidence interval;
Putzu et al. (26, 29) .
DISCUSSION
The main finding of this meta-analysis is that furosemide with matched hydration by the RenalGuard System may reduce the incidence of CI-AKI in highpri nt & web 4C=FPO
FIGURE 3 Meta-Analysis Comparing the Effects of RenalGuard Therapy Versus Control Group on Secondary Clinical Outcomes
A nonsignificant lower incidence of stroke, acute coronary syndromes, and pulmonary edema was found in the RenalGuard group compared with the control group.
Abbreviations as in Figure 2 .
Putzu et al. 
CONCLUSIONS
The main findings of this meta-analysis is that furo- 
